Sarda Energy & Minerals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 29, 2025, 4:14 pm

Competitors of Sarda Energy & Minerals Ltd

All Competitor Stocks of Sarda Energy & Minerals Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:53 am

Below is a detailed analysis of the quarterly data for Sarda Energy & Minerals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 1,239.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,319.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 80.00 Cr..
• For Expenses, as of Mar 2025, the value is 968.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 950.00 Cr. (Dec 2024) to 968.00 Cr., marking an increase of 18.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 271.00 Cr.. The value appears to be declining and may need further review. It has decreased from 369.00 Cr. (Dec 2024) to 271.00 Cr., marking a decrease of 98.00 Cr..
• For OPM %, as of Mar 2025, the value is 22.00%. The value appears to be declining and may need further review. It has decreased from 28.00% (Dec 2024) to 22.00%, marking a decrease of 6.00%.
• For Other Income, as of Mar 2025, the value is 46.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Dec 2024) to 46.00 Cr., marking an increase of 46.00 Cr..
• For Interest, as of Mar 2025, the value is 70.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 64.00 Cr. (Dec 2024) to 70.00 Cr., marking an increase of 6.00 Cr..
• For Depreciation, as of Mar 2025, the value is 87.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 78.00 Cr. (Dec 2024) to 87.00 Cr., marking an increase of 9.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 160.00 Cr.. The value appears to be declining and may need further review. It has decreased from 226.00 Cr. (Dec 2024) to 160.00 Cr., marking a decrease of 66.00 Cr..
• For Tax %, as of Mar 2025, the value is 41.00%. The value appears to be increasing, which may not be favorable. It has increased from 17.00% (Dec 2024) to 41.00%, marking an increase of 24.00%.
• For Net Profit, as of Mar 2025, the value is 100.00 Cr.. The value appears to be declining and may need further review. It has decreased from 200.00 Cr. (Dec 2024) to 100.00 Cr., marking a decrease of 100.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 3.07. The value appears to be declining and may need further review. It has decreased from 5.60 (Dec 2024) to 3.07, marking a decrease of 2.53.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:13 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:24 am

Below is a detailed analysis of the balance sheet data for Sarda Energy & Minerals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 35.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 35.00 Cr..
• For Reserves, as of Mar 2025, the value is 6,251.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,853.00 Cr. (Mar 2024) to 6,251.00 Cr., marking an increase of 2,398.00 Cr..
• For Borrowings, as of Mar 2025, the value is 2,861.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,366.00 Cr. (Mar 2024) to 2,861.00 Cr., marking an increase of 1,495.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 977.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 747.00 Cr. (Mar 2024) to 977.00 Cr., marking an increase of 230.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 10,125.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,002.00 Cr. (Mar 2024) to 10,125.00 Cr., marking an increase of 4,123.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 5,854.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,853.00 Cr. (Mar 2024) to 5,854.00 Cr., marking an increase of 3,001.00 Cr..
• For CWIP, as of Mar 2025, the value is 613.00 Cr.. The value appears strong and on an upward trend. It has increased from 251.00 Cr. (Mar 2024) to 613.00 Cr., marking an increase of 362.00 Cr..
• For Investments, as of Mar 2025, the value is 792.00 Cr.. The value appears strong and on an upward trend. It has increased from 659.00 Cr. (Mar 2024) to 792.00 Cr., marking an increase of 133.00 Cr..
• For Other Assets, as of Mar 2025, the value is 2,867.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,239.00 Cr. (Mar 2024) to 2,867.00 Cr., marking an increase of 628.00 Cr..
• For Total Assets, as of Mar 2025, the value is 10,125.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,002.00 Cr. (Mar 2024) to 10,125.00 Cr., marking an increase of 4,123.00 Cr..

Notably, the Reserves (6,251.00 Cr.) exceed the Borrowings (2,861.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Sarda Energy & Minerals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 19.86. This value is within the healthy range. It has increased from 14.84 (Mar 24) to 19.86, marking an increase of 5.02.
• For Diluted EPS (Rs.), as of Mar 25, the value is 19.86. This value is within the healthy range. It has increased from 14.84 (Mar 24) to 19.86, marking an increase of 5.02.
• For Cash EPS (Rs.), as of Mar 25, the value is 27.03. This value is within the healthy range. It has increased from 19.63 (Mar 24) to 27.03, marking an increase of 7.40.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 178.39. It has increased from 110.35 (Mar 24) to 178.39, marking an increase of 68.04.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 178.39. It has increased from 110.35 (Mar 24) to 178.39, marking an increase of 68.04.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 131.75. It has increased from 109.77 (Mar 24) to 131.75, marking an increase of 21.98.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 40.00. This value is within the healthy range. It has increased from 27.87 (Mar 24) to 40.00, marking an increase of 12.13.
• For PBIT / Share (Rs.), as of Mar 25, the value is 32.30. This value is within the healthy range. It has increased from 22.66 (Mar 24) to 32.30, marking an increase of 9.64.
• For PBT / Share (Rs.), as of Mar 25, the value is 26.04. This value is within the healthy range. It has increased from 18.94 (Mar 24) to 26.04, marking an increase of 7.10.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 19.33. This value is within the healthy range. It has increased from 14.43 (Mar 24) to 19.33, marking an increase of 4.90.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.86. This value is within the healthy range. It has increased from 14.84 (Mar 24) to 19.86, marking an increase of 5.02.
• For PBDIT Margin (%), as of Mar 25, the value is 30.36. This value is within the healthy range. It has increased from 25.38 (Mar 24) to 30.36, marking an increase of 4.98.
• For PBIT Margin (%), as of Mar 25, the value is 24.51. This value exceeds the healthy maximum of 20. It has increased from 20.64 (Mar 24) to 24.51, marking an increase of 3.87.
• For PBT Margin (%), as of Mar 25, the value is 19.76. This value is within the healthy range. It has increased from 17.25 (Mar 24) to 19.76, marking an increase of 2.51.
• For Net Profit Margin (%), as of Mar 25, the value is 14.67. This value exceeds the healthy maximum of 10. It has increased from 13.14 (Mar 24) to 14.67, marking an increase of 1.53.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.07. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 15.07, marking an increase of 1.55.
• For Return on Networth / Equity (%), as of Mar 25, the value is 11.13. This value is below the healthy minimum of 15. It has decreased from 13.44 (Mar 24) to 11.13, marking a decrease of 2.31.
• For Return on Capital Employeed (%), as of Mar 25, the value is 12.51. This value is within the healthy range. It has decreased from 15.29 (Mar 24) to 12.51, marking a decrease of 2.78.
• For Return On Assets (%), as of Mar 25, the value is 6.91. This value is within the healthy range. It has decreased from 8.71 (Mar 24) to 6.91, marking a decrease of 1.80.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.37. This value is within the healthy range. It has increased from 0.27 (Mar 24) to 0.37, marking an increase of 0.10.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 0.44, marking an increase of 0.09.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.57. It has decreased from 0.67 (Mar 24) to 0.57, marking a decrease of 0.10.
• For Current Ratio (X), as of Mar 25, the value is 3.06. This value exceeds the healthy maximum of 3. It has decreased from 3.36 (Mar 24) to 3.06, marking a decrease of 0.30.
• For Quick Ratio (X), as of Mar 25, the value is 2.27. This value exceeds the healthy maximum of 2. It has decreased from 2.69 (Mar 24) to 2.27, marking a decrease of 0.42.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.73. This value is below the healthy minimum of 4. It has increased from 3.64 (Mar 24) to 3.73, marking an increase of 0.09.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 10.10 (Mar 24) to 0.00, marking a decrease of 10.10.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 7.48 (Mar 24) to 0.00, marking a decrease of 7.48.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 89.90 (Mar 24) to 0.00, marking a decrease of 89.90.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 92.52 (Mar 24) to 0.00, marking a decrease of 92.52.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 6.40. This value is within the healthy range. It has decreased from 7.65 (Mar 24) to 6.40, marking a decrease of 1.25.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.10. This value is within the healthy range. It has decreased from 4.98 (Mar 24) to 4.10, marking a decrease of 0.88.
• For Enterprise Value (Cr.), as of Mar 25, the value is 20,321.00. It has increased from 7,861.30 (Mar 24) to 20,321.00, marking an increase of 12,459.70.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.38. This value exceeds the healthy maximum of 3. It has increased from 2.03 (Mar 24) to 4.38, marking an increase of 2.35.
• For EV / EBITDA (X), as of Mar 25, the value is 14.41. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 14.41, marking an increase of 6.40.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has increased from 1.85 (Mar 24) to 3.88, marking an increase of 2.03.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 89.89 (Mar 24) to 0.00, marking a decrease of 89.89.
• For Price / BV (X), as of Mar 25, the value is 2.86. This value is within the healthy range. It has increased from 1.84 (Mar 24) to 2.86, marking an increase of 1.02.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has increased from 1.85 (Mar 24) to 3.88, marking an increase of 2.03.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.03, marking a decrease of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness